1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Glocal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; doi: 10.3322/caac.21492.

2. Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, et al. Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016;122:1312-37.

3. Khan FZ, Perumpail RB, Wong RJ, Ahmed A. Advances in hepatocellular carcinoma: nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol 2015;7:2155-61.

4. Kolly P, Dufour JF. Surveillance for hepatocellular carcinoma in patients with NASH. Diagnostics (Basel) 2016; doi: 10.3390/diagnostics6020022.

5. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014;109:542-53.

6. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-16.

7. National Center for Health Statistics (US). Health, United States, 2016: with chartbook on long-term trends in health. Available from: [Last accessed on 11 Oct 2018].

8. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr Rev 2016;37:278-316.

9. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011;46:63-9.

10. Gan L, Chitturi S, Farrell GC. Mechanisms and implications of age-related changes in the liver: nonalcoholic fatty liver disease in the elderly. Curr Gerontol Geriatr Res 2011;2011:831536.

11. Iyer JK, Kalra M, Kaul A, Payton ME, Kaul R. Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis. World J Gastroenterol 2017;23:6802-16.

12. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.

13. Bruix J, Sherman M, Committee Practice Guidelines, Diseases American Association for the Study of Liver. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.

14. Edge S, Byrd DR, Compton CC, Fritz AG, Greene F, et al. AJCC cancer staging manual 7th ed. New York: Springer; 2009. pp. 191-9.

15. Klein SL. Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. Bioessays 2012;34:1050-9.

16. White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ, et al. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology 2012;55:759-68.

17. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121-4.

18. Di Martino V, Lebray P, Myers RP, Pannier E, Paradis V, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 2004;40:1426-33.

19. Liu WC, Liu QY. Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2014;20:6252-61.

20. Cho LY, Yang JJ, Ko KP, Park B, Shin A, et al. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer 2011;128:176-84.

21. Purohit V, Rapaka R, Kwon OS, Song BJ. Roles of alcohol and tobacco exposure in the development of hepatocellular carcinoma. Life Sci 2013;92:10.

22. Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer 2016;122:1757-65.

23. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11-20.

24. Setiawan VW, Lim U, Lipworth L, Lu SC, Shepherd J, et al. Sex and ethnic differences in the association of obesity with risk of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2016;14:309-16.

25. Yang JD, Abdelmalek MF, Pang H, Guy CD, Smith AD, et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014;59:1406-14.

26. Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, et al. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther 2017;34:1291-1326.

27. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624.

28. Singal AG, Volk ML, Rakoski MO, Fu S, Su GL, et al. Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. J Clin Gastroenterol 2011;45:727-32.

29. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010;52:132-41.

30. Palmer LB, Kappelman MD, Sandler RS, Hayashi PH. Surveillance for hepatocellular carcinoma in a medicaid cirrhotic population. J Clin Gastroenterol 2013;47:713-8.

31. Ahmed Mohammed HA, Yang JD, Giama NH, Choi J, Ali HM, et al. Factors influencing surveillance for hepatocellular carcinoma in patients with liver cirrhosis. Liver Cancer 2017;6:126-36.

32. Farinati F, Sergio A, Giacomin A, Di Nolfo MA, Del Poggio P, et al. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Eur J Gastroenterol Hepatol 2009;21:1212-8.

33. Simon TG, King LY, Chong DQ, Nguyen LH, Ma Y, et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies. Hepatology 2018;67:1797-1806.

34. Moylan CA, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, et al. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008;300:2371-8.

35. Bryce CL, Angus DC, Arnold RM, Chang CC, Farrell MH, et al. Sociodemographic difference in early access to liver transplant services. Am J Transplant 2009;9:2092-101.

36. Oloruntoba OO, Moylan CA. Gender-based disparities in access to and outcomes of liver transplantation. World J Hepatol 2015;7:460-7.

37. Allen AM, Heimbach JK, Larson JJ, Mara KC, Kim WR, et al. Reduced access to liver transpaltnation in women: role of height, MELD exception scores, and renal function underestimation. Transplantation 2018;102:1710-6.

38. Cholongitas E, Marelli L, Kerry A, Goodier DW, Nair D, et al. Female liver transplant recipients with the same GFR as male recipients have lower MELD scores--a systematic bias. Am J Transplant 2007;7:685-92.

39. Lai JC, Terrault NA, Vittinghoff E, Biggins SW. Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system. Am J Transplant 2010;10:2658-64.

40. Yang D, Hanna DL, Usher J, LoCoco J, Chaudhari P, et al. Impact of sex on the survival of patients with hepatocellular carcinoma: a surveillance, epidemiology, and end results analysis. Cancer 2014;120:3707-16.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: